𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial

✍ Scribed by Paolo Barone; Werner Poewe; Stefan Albrecht; Catherine Debieuvre; Dan Massey; Olivier Rascol; Eduardo Tolosa; Daniel Weintraub

Book ID
114409516
Publisher
The Lancet
Year
2010
Tongue
English
Weight
219 KB
Volume
9
Category
Article
ISSN
1474-4465

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Sarizotan as a treatment for dyskinesias
Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial
✍ Christopher G. Goetz; Philippe Damier; Christine Hicking; Eugene Laska; Thomas M πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 117 KB πŸ‘ 1 views

## Abstract The objective of this study is to conduct a dose‐finding study of sarizotan in Parkinson's disease (PD) patients with dyskinesia to identify a safe dose and to identify a sensitive dyskinesia rating measure. Sarizotan is a novel compound with full 5‐HT~1A~ agonist properties and additio

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease
✍ Kitty K. Wong; Jane E. Alty; Amanda G. Goy; Sanjay Raghav; David C. Reutens; Pet πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 565 KB

## Abstract ## Background: This randomized double blind, placebo‐controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease. ## Methods: Sixteen participants with levodopa‐induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments s